Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction

Rev Esp Cardiol (Engl Ed). 2021 Dec;74(12):1117-1119. doi: 10.1016/j.rec.2021.06.005. Epub 2021 Jul 8.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aminobutyrates* / therapeutic use
  • Angiotensin Receptor Antagonists / therapeutic use
  • Biphenyl Compounds
  • Drug Combinations
  • Heart Failure* / drug therapy
  • Humans
  • Stroke Volume
  • Tetrazoles
  • Treatment Outcome
  • Valsartan
  • Ventricular Function, Left

Substances

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • sacubitril
  • Valsartan